Vanda Pharmaceuticals expands into cystic fibrosis, blood cancer
D.C.-based Vanda Pharmaceuticals Inc. has expanded its portfolio to include research and development into treatments for cystic fibrosis and blood cancer.
During a first-quarter earnings call this week, CEO Mihael Polymeropoulos said Vanda (NASDAQ: VNDA) is on track to file an investigational new drug application to the Food and Drug Administration in mid-2017 to start a new clinical trial in patients with blood cancers.
Meanwhile, in March, Vanda agreed to pay up to $46 million to the University…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Tina Reed Source Type: news